U.S. FDA approves ChemoCentryx drug to treat rare autoimmune disease

Published by

(Reuters) – The U.S. Food and Drug Administration on Friday approved ChemoCentryx Inc’s lead drug candidate, Avacopan, for treating a rare, fatal autoimmune disease, the biopharmaceutical company said. (Reporting by Oishee Majumdar and Dania Nadeem in Bengaluru; Editing by Anil D’Silva)

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *